Cross-Sector entity
Lantheus Holdings is most often covered alongside Heron Therapeutics, which appears in 8 of these 8 stories. Coverage clusters in earnings, which accounts for 3 of those 8, with the remainder spread across 2 other categories. Negative sentiment appears in 0% of the tracked stories.
8 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Lantheus Holdings is most often covered alongside Heron Therapeutics, which appears in 8 of these 8 stories. Coverage clusters in earnings, which accounts for 3 of those 8, with the remainder spread across 2 other categories. Negative sentiment appears in 0% of the tracked stories. Each carries 4.5 original sources on average. This profile follows 8 Cross-Sector stories mentioning Lantheus Holdings across the period from February 25, 2026 to February 26, 2026.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lantheus Holdings. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter financial results, highlighting a period of transition for the mid-cap biotech sector. While both companies provided initial FY26 outlooks, market attention is shifting toward their respective commercial scaling efforts and pipeline execution.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Source: Seeking Alpha · Seeking Alpha
A wave of Q4 2025 earnings previews highlights the growing intersection of specialized SaaS platforms and high-stakes medical and infrastructure sectors. Companies like Delcath Systems and Bentley Systems are under scrutiny as investors look for evidence of commercial scaling and software-driven efficiency gains.
Source: Seeking Alpha · Seeking Alpha
As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Delcath Systems, Lantheus Holdings, Butterfly Network, and Heron Therapeutics are preparing to report Q4 2025 earnings, marking a critical test for commercial-stage medical innovators. Investors are laser-focused on the adoption rates of flagship products like HEPZATO KIT and PYLARIFY as these companies navigate a complex reimbursement environment.
Source: Seeking Alpha · Seeking Alpha
